Recognition of Small Polar Molecules with an Ionic Crystal of α-Keggin-Type Polyoxometalate with a Macrocation by Sayaka Uchida (115177)

“…The space volumes of the ionic crystals decrease in the order of <b>1a</b> > <b>2a</b> > <b>3a</b> > <b>4a</b>. …”

Recognition of Small Polar Molecules with an Ionic Crystal of α-Keggin-Type Polyoxometalate with a Macrocation by Sayaka Uchida (115177)

“…The space volumes of the ionic crystals decrease in the order of <b>1a</b> > <b>2a</b> > <b>3a</b> > <b>4a</b>. …”

Recognition of Small Polar Molecules with an Ionic Crystal of α-Keggin-Type Polyoxometalate with a Macrocation by Sayaka Uchida (115177)

“…The space volumes of the ionic crystals decrease in the order of <b>1a</b> > <b>2a</b> > <b>3a</b> > <b>4a</b>. …”

<i>Tg</i>6PGDH2 is important for parasite survival. by Ningbo Xia (13584299)

Impact of Hyperglycemia and Low Oxygen Tension on Adipose-Derived Stem Cells Compared with Dermal Fibroblasts and Keratinocytes: Importance for Wound Healing in Type 2 Diabetes - F... by Aurore Lafosse (816357)

“…No significant difference was observed between the two populations. The mean expansion time to passage 4 was 58.5 days (±18 days) for diabetic ASC versus 62.5 days (±28 days) for ND ASC (<i>p</i> = NS). …”

Image_2_A Two-Gene-Based Diagnostic Signature for Ruptured Intracranial Aneurysms.TIF by Yuwang Li (11270949)

Image_1_A Two-Gene-Based Diagnostic Signature for Ruptured Intracranial Aneurysms.JPEG by Yuwang Li (11270949)

Endothelial cell tropism is a determinant of H5N1 pathogenesis in mammalian species by Smanla Tundup (376040)

Image_3_A Two-Gene-Based Diagnostic Signature for Ruptured Intracranial Aneurysms.TIF by Yuwang Li (11270949)

An efficient coding theory for a dynamic trajectory predicts non-uniform allocation of entorhinal grid cells to modules by Noga Mosheiff (4116820)

MTT assay and isobologram analysis showing the effect of bort/venetoclax on the cell viability of BL2 EBV-negative/WT EBV pair, BL31 EBV-negative/WT EBV pair, sLCL 381, and sLCL 42... by Kam Pui Tam (19746865)

<i>Tg</i>G6PDH1, <i>Tg</i>G6PDH2, <i>Tg</i>6PGDH1, <i>Tg</i>RuPE and <i>Tg</i>TAL are dispensable for parasite growth and virulence, while <i>Tg</i>G6PDHs are required for defendin... by Ningbo Xia (13584299)

pI7L inhibits STAT1 phosphorylation and blocks its nuclear translocation. by Meilin Li (1832905)

pI7L suppresses the IFN-<i>γ</i>-triggered JAK-STAT signaling pathway. by Meilin Li (1832905)

The Potential of Antimicrobials to Induce Thrombocytopenia in Critically Ill Patients: Data from a Randomized Controlled Trial by Maria Egede Johansen (490779)

Shifts caused by control and Grin2c siRNAs in stimulation threshold and maximum response rate. by Giovanni Hernandez (236411)

“…<p><b>A-B)</b> Histogram bars represent means +/- SEM; saline injection in the VTA does not produces a reliable change in M50 nor MAX <b>C)</b> Treatment with the control siRNA did not produce a significant change in the stimulation threshold (M50), but the treatment with the siRNA against the Grin2c subunit produces a significant increase. …”

Mapping changes in patterning after inhibition of Notch activity. by Matthew French (13007466)

“…<p><b>A:</b> Culture method where a posterior explant of an E8.5 embryo is cultured in N2B27 media with the Notch inhibitor LY at 150 nM or an equal amount of DMSO for 12 h. …”

pI7L inhibits the phosphorylation of STAT1 depending on its tyrosine at position 98. by Meilin Li (1832905)

The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data by The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group (614261)

“…After adjusting for confounding factors, the mg/kg dose of piperaquine was found to be a significant predictor for recrudescence, the risk increasing by 13% (95% CI 5.0%–21%) for every 5 mg/kg decrease in dose; <i>p</i> = 0.002. …”

Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study by Jung-Ick Byun (554902)

“…Seizure frequency was evaluated at 2–4 weeks and 6 months after the onset of the initial immunotherapy and was categorized as “seizure remission”, “> 50% seizure reduction”, or “no change” based on the degree of its decrease.…”